Relative survival with and without radioiodine therapy in intermediate risk papillary thyroid cancer and low risk, minimally invasive follicular thyroid cancer. (IMAGE)

Society of Nuclear Medicine and Molecular Imaging

Relative survival with and without radioiodine therapy in intermediate risk papillary thyroid cancer and low risk, minimally invasive follicular thyroid cancer.

Caption

Graphical Abstract. Relative survival with and without radioiodine therapy (RAI) in intermediate risk papillary thyroid cancer (PTC) and low risk, minimally invasive follicular thyroid cancer (FTC). A higher survival rate after undergoing radioiodine therapy begins to emerge after approximately 8 years. 

Credit

Images created by Henning Weis, PhD, MD and Prof. Matthias Schmidt, MD, FEBNM: Nuclear medicine physicians at the Department of Nuclear Medicine, University Hospital of Cologne.

Usage Restrictions

Please give appropriate credit.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.